QuidelOrtho (NASDAQ:QDEL) reports sales below analyst estimates in Q3 2026 earnings, stock drops 10.6%
QuidelOrtho (QDEL) reported Q3 2026 revenue of $618.9M, missing estimates by 2.5% and down 11.6% YoY. Adjusted EPS beat estimates at $0.31. Full-year revenue guidance was lowered to $2.53B. The stock dropped 10.6% post-earnings. Management cited challenges in China and a softer respiratory season but outlined cost-cutting plans.
How this was made

The 30-second read
Why it matters
Revenue miss and guidance cut drive negative sentiment; however, an EPS beat and cost‑cut plan may mitigate long‑term concerns.
Market read
The earnings surprise and guidance downgrade triggered a 10.6% drop, making the story highly relevant for short‑term traders in the healthcare diagnostics space.
What to watch
Potential upside from cost‑transformation initiatives and a durable installed base in labs and immunohematology.
Background
QuidelOrtho is a U.S. diagnostics firm with a market cap around $962 M; its Q3 results were released on Nov 3 2026.
Ticker impact
QDEL reported Q3 2026 revenue miss and lowered full-year guidance, causing a 10.6% stock drop.
likely further downside as investors price in weaker revenue outlook
Revenue fell 11.6% YoY, missed estimates, and full‑year revenue guidance was cut 1.2%; EPS guidance also lowered, prompting immediate sell‑off.
Market effects
Diagnostic and lab‑testing sector may face pressure as QDEL signals weaker demand and softer respiratory season.
U.S. healthcare stocks could see modest pullback in early trading.
Limited; primarily affects U.S. listed health‑care diagnostics peers.
Counterpoint
The EPS beat and cost‑reduction program could support a rebound if guidance is revised upward later.
Key entities
- ExecutiveBrian J. Blaser
President and CEO of QuidelOrtho, quoted on cost‑transformation plan.


